WOCKPHARMAWockhardt Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · ICRA: A- (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.4 this quarter.
Momentum from moving averages, Supertrend and RSI.
4 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
4 found · risk watch
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹969 Cr | ₹73 Cr | 12.18% | 7.53% | ₹4.85 | 2.3x |
| Q1 FY2027 | ₹929 Cr | ₹107 Cr | 14.75% | 11.52% | ₹6.55 | 3.2x |
| Q4 FY2026 | ₹965 Cr | ₹164 Cr | 17.82% | 16.99% | ₹10.23 | 4.8x |
| Q3 FY2026 | ₹888 Cr | ₹61 Cr | 12.61% | 6.87% | ₹3.61 | 2.1x |
| Q2 FY2026 | ₹782 Cr | ₹82 Cr | 15.98% | 10.49% | ₹4.81 | 2.7x |
| Q1 FY2026 | ₹738 Cr | ₹-108 Cr | 2.17% | -14.63% | ₹-5.53 | -1.3x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.